Magnesium sulphate for acute bronchiolitis in children under two years of age

Nebulised treatment

To read the full review go to Magnesium sulphate for treating acute bronchiolitis in children under two years of age

Plain language summary

Key messages

  • It is unclear if magnesium sulphate, either alone or combined with other treatments, improves patient outcomes in children under two years old with bronchiolitis.
  • Future large, well‐designed studies are needed looking at the benefits and harms of magnesium sulphate in acute bronchiolitis.

What is acute bronchiolitis?

Acute bronchiolitis is a common lung infection in children under two years of age. Small airways in the lungs become blocked, causing coughing, wheezing, and difficulty breathing. Bronchiolitis is caused by a virus. Usual treatment involves supportive care, which includes adequate fluids and humidified oxygen. Children with bronchiolitis may need intensive care treatment.

What did we want to find out?

We wanted to find out if magnesium sulphate, either alone or combined with other treatments, is more effective and safer compared to other treatment options for acute bronchiolitis.

What did we do?

We searched for and included studies that compared magnesium sulphate (alone or in combination with other treatments) with other treatment options. We combined the results of these studies and rated our confidence in the evidence based on study methods and sizes.

What did we find?

We included seven studies (816 children) conducted in Qatar, Turkey, Iran, China, and India. Four studies included children with moderate to severe bronchiolitis. Studies compared magnesium sulphate, given via a tube into a vein (intravenous) or as a fine inhaled spray (nebulised), with a dummy treatment (placebo), medicines to open the airways (salbutamol or epinephrine), a salt water solution (hypertonic saline), usual treatment (oxygen and adequate fluids), or no treatment.

It is unclear if magnesium sulphate alone or combined with other treatments improves outcomes such as reduced deaths, unexpected medical problems during treatment, time spent in hospital, or illness severity (based on doctors' clinical assessment scores). Time taken to recover was not measured.

What are the limitations of the evidence?

Overall, we have very low confidence in the evidence, mainly because the included studies involved few children, and there were problems with the study methods. Further research is likely to change the results of this review.

How up‐to‐date is the evidence?

The evidence is current to November 2024.